Izeltabart (IMGC-936) is a Maytansinoid-based Antibody-Drug Conjugate (ADC) that specifically targets ADAM9. It consists of a high-affinity humanized antibody conjugated site-specifically to DM21-C, a linker-payload that combines a microtubule-disrupting Maytansinoid with a stable tripeptide linker, maintaining a drug-to-antibody ratio of approximately 2.0. Izeltabart demonstrates cytotoxicity against ADAM9-expressing human tumor cell lines and possesses significant antitumor efficacy in xenograft tumor models [1].